N-(4-Bromobenzyl)-5-methoxytryptamine oxalate

Discontinued Product

N-(4-Bromobenzyl)-5-methoxytryptamine oxalate (Cat. No. 0755) has been withdrawn from sale for commercial reasons.
Cat.No. 0755 - N-(4-Bromobenzyl)-5-methoxytryptamine oxalate
Description: 5-HT2A ligand
Datasheet
Citations
Reviews
Literature

Biological Activity

Very potent and selective ligand at 5-HT2A receptors (Ki = 0.1 nM).

Technical Data

M. Wt 449.3
Storage Desiccate at +4°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Safety Datasheet

References

References are publications that support the biological activity of the product.

Glennon et al (1994) Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. J.Med.Chem. 37 1929 PMID: 8027974

View Related Products by Target

View Related Products by Product Action

View all 5-HT2A Receptor Ligands

Keywords: N-(4-Bromobenzyl)-5-methoxytryptamine oxalate, N-(4-Bromobenzyl)-5-methoxytryptamine oxalate supplier, 5-HT2A, Receptors, 0755, Tocris Bioscience

Citations for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate

Citations are publications that use Tocris products.

Currently there are no citations for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate.

Reviews for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate

There are currently no reviews for this product. Be the first to review N-(4-Bromobenzyl)-5-methoxytryptamine oxalate and earn rewards!

Have you used N-(4-Bromobenzyl)-5-methoxytryptamine oxalate?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.